

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	12M5.41
True Name	Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Vaccine, Standard & Variant, Mass & Ark Types, Killed Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Bursa Guard N-B-R - No distributor specified
Date of Compilation Summary	May 17, 2019

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

124 12M5.41 Page 1 of 19

Study Type	Efficacy
Pertaining to	Infectious bursal disease, standard and variant E
Study Purpose	Demonstrate efficacy in stimulating passive immunity in offspring
	of birds vaccinated against infectious bursal disease, standard and
	variant E
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	August 27, 1992

124 12M5.41 Page 2 of 19

Study Type	Efficacy
Pertaining to	Infectious bursal disease, standard and variant E
Study Purpose	Demonstrate efficacy against bursal disease, standard and
_	variant E
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	January 21, 2005

124 12M5.41 Page 3 of 19

Study Type	Efficacy
Pertaining to	Infectious bronchitis virus, Arkansas type
Study Purpose	Demonstrate efficacy against infectious bronchitis virus, Arkansas
	type
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	January 21, 2005

124 12M5.41 Page 4 of 19

Study Type	Efficacy
Pertaining to	Infectious bronchitis virus, Massachusetts type
Study Purpose	Demonstrate efficacy against infectious bronchitis virus,
	Massachusetts type
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	January 21, 2005

124 12M5.41 Page 5 of 19

Study TypeEfficacyPertaining toInfectious bronchitis virus, Massachusetts typeStudy PurposeDemonstrate efficacy against infectious bronchitis virus, Massachusetts type vaccineProduct AdministrationOne dose intramuscularly (IM) on study Day 21Study AnimalsTwelve-week-old SPF chicks; 24-25 per group; Group 9 was primed at 9 weeks of age on study Day 0 with a live IBV Mass vaccine.Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Study PurposeDemonstrate efficacy against infectious bronchitis virus, Massachusetts type vaccineProduct AdministrationOne dose intramuscularly (IM) on study Day 21Study AnimalsTwelve-week-old SPF chicks; 24-25 per group; Group 9 was primed at 9 weeks of age on study Day 0 with a live IBV Mass vaccine.Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Massachusetts type vaccine Product Administration One dose intramuscularly (IM) on study Day 21 Twelve-week-old SPF chicks; 24-25 per group; Group 9 was primed at 9 weeks of age on study Day 0 with a live IBV Mass vaccine. Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Product Administration Study Animals Twelve-week-old SPF chicks; 24-25 per group; Group 9 was primed at 9 weeks of age on study Day 0 with a live IBV Mass vaccine. Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Study Animals Twelve-week-old SPF chicks; 24-25 per group; Group 9 was primed at 9 weeks of age on study Day 0 with a live IBV Mass vaccine. Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
primed at 9 weeks of age on study Day 0 with a live IBV Mass vaccine. Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Group 7: No priming; No vaccine; IBV Mass challenge Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Group 9: Primed; Vaccinated; IBV Mass challenge Group 13: No priming; No vaccine; no challenge
Group 13: No priming; No vaccine; no challenge
Challenge Description Infectious bronchitis, Mass type on study Day 42
Interval observed after Five days post challenge, the tracheas were harvested for tracheal
challenge ring evaluation and virus re-isolation of the strains used for the
challenge.
Results Tracheal ring scores: A bird was considered affected if less than
50% of a tracheal ring section had discernible ciliary activity in
any of three samples (representing the upper third, middle third,
and lower third of the trachea). Each bird received a score from 0
3 depending on how many sections were affected.
Number of offeeted binder
Number of affected birds:
Group 7: 25/25 (unvaccinated control) Group 9: 0/25
Group 9: 0/25 Group 13: 0/25 (non-challenged control)
Group 13. 0/23 (non-chancinged control)
Virus Isolation: A bird was considered affected if any embryos
died after each tracheal swab was used to inoculate 5 embryonate
eggs. Each bird received a score from 0-5 based on the number of
embryos that died.
Chibi yos that died.
Number of affected birds:
Group 7: 25/25 (unvaccinated control)
Group 9: 3/25
Group 13: 0/25 (non-challenged control)
Storp to: 0, 20 (non onanongou control)
Raw data on attached page.
USDA Approval Date June 3, 2008

124 12M5.41 Page 6 of 19

Tracheal Ring Scores - Raw data

Tracheal Score, individual Results

Three 2 mm wide tracheal rings representing the upper third, middle third and lower third of the trachea of each bird were examined for ciliary activity. Tracheal ring sections were considered positive if less than 50% of the ring had discernible ciliary activity. Each bird received a score of 0, 1, 2, or 3 depending on how many sections were positive. A score of zero indicated that all sections were negative. A score of three indicated that all sections were positive. A score ≥ 1 is considered affected.

Group	vaccine	challenge	Unit	ID	Score
7	None	MASS	7	381	3
				382	3
				383	3
				384	3
				385	3
				386	3
				387	3
				388	3
				389	3
				390	3
				391	3
				392	3
				393	3
			8	394	3
				395	3
				396	3
				397	3
				398	3
				399	3
				400	3
				401	3
				402	3
				403	3
				404 40E	3
9	Vaccine	MASS	3	405 331	0
'	Vaccilie	IVIAGG	3	332	0
				333	0
				334	0
				335	0
				336	0
				337	0
				338	0
				339	0
				340	0
		<u> </u>	II	340	U

124 12M5.41 Page 7 of 19

Group	vaccine	challenge	Unit	ID	Score
				341	0
				342	0
				343	0
			4	344	0
				345	0
				346	0
				347	0
				348	0
				349	0
				350	0
				351	0
				352	0
				353	0
				354	0
				355	0
13	None	N/A	1	306	0
				307	0
				308	0
				309	0
				310	0
				311	0
				312	0
				313	0
				314	0
				315	0
				316	0
				317	0
			2	318	0
			2	319	0
				320	0
				321	0
				322 323	0
				324	0
				325	0
				326	0
				327	0
				328	0
				329	0
				330	0

 $\ensuremath{\mathsf{MASS}} = \ensuremath{\mathsf{Infectious}}$ bronchitis virus, Massachusetts type $\ensuremath{\mathsf{N/A}} = \ensuremath{\mathsf{Not}}$ applicable

124 12M5.41 Page 8 of 19

Virus Isolation (VI) - Raw data

VI Score, individual results

Each tracheal swab was used to inoculate 5 embryonated eggs. Each bird received a score of 0, 1, 2, 3, 4 or 5 depending on how many embryos died. A score of zero indicated that none of the embryos died and a score of 5 indicated that all five of the embryos died. A score ≥ 1 is considered affected.

Group	vaccine	challenge	Unit	ID	Score
7	None	MASS	7	381	5
				382	4
				383	5
				384	5
				385	5
				386	4
				387	3
				388	3
				389	5
				390	4
				391	3
				392	3
				393	3
			8	394	5
				395	5
				396	2
				397	5
				398	4
				399	4
				400	4
				401	5
				402	4
				403	5
				404	5
				405	5
9	Vaccine	MASS	3	331	4
				332	0
				333	0
				334	
				335	0
				336	0
				337	0
				338	0
				339	0
				340	0
				341	0

124 12M5.41 Page 9 of 19

Group	vaccine	challenge	Unit	חו	Score
Стоир	Vaccine	oriunerige	Oint	342	0
				343	0
			4	344	0
•				345	0
				346	0
				347	0
				348	
				349	3
				350	0
				351	0
				352	0
				353	0
				354	0
				355	0
				507	0
				508	0
				509	
				510	0
				511	0
				512	
				513	0
				514	0
				515	0
				516	0
				518	0
			24	519	0
				520	0
				521	0
				522	0
				523	0
				524	0
				525	0
				526	0
				527	0
				528	0
				529	0
				530	0
13	None	N/A	1	306	0
				307	0
				308	0
				309	0
				310	0
				311	0
				312	0
				313	0
				314	0
ľ				315	0
				316	0

124 12M5.41 Page 10 of 19

Group	vaccine	challenge	Unit	ID	Score
				317	0
				318	0
			2	319	0
				320	0
				321	0
				322	0
				323	0
]				324	0
				325	0
]				326	0
				327	0
				328	0
				329	0
				330	0

 $\label{eq:MASS} \mbox{ = Infectious bronchitis virus, Massachusetts type } \mbox{ N/A = Not applicable}$

124 12M5.41 Page 11 of 19

Study Type	Efficacy				
Pertaining to	Infectious bronchitis virus, Arkansas type				
Study Purpose	Demonstrate efficacy against infectious bronchitis virus, Arkansas				
	type				
Product Administration	One dose intramuscularly (IM) on study Day 21				
Study Animals	Twelve-week-old SPF chicks; 23-25 per group; Group 3 primed at				
	9 weeks of age on study Day 0 with a live IBV Ark vaccine,				
	Group 1: No priming; No vaccine; IBV Ark challenge				
	Group 3: Primed; Vaccinated; IBV Ark challenge				
	Group 13: No priming; No vaccine; no challenge				
Challana Danaintian	Trefordings have abidis. A distance on steeler Day 42				
Challenge Description	Infectious bronchitis, Ark type on study Day 42				
Interval observed after	Five days post challenge, the tracheas were harvested for tracheal ring evaluation and virus re-isolation of the strains used for the				
challenge	challenge.				
Results	Tracheal ring scores: A bird was considered affected if less than				
Results	50% of a tracheal ring section had discernible ciliary activity in				
	any of three samples (representing the upper third, middle third,				
	and lower third of the trachea). Each bird received a score from 0-				
	3 depending on how many sections were affected.				
	Number of affected birds:				
	Group 1: 25/25 (unvaccinated control)				
	Group 3: 1/24				
	Group 13: 0/25 (non-challenged control)				
	Viena Tall-40 and A bind and a side of a side of the s				
	Virus Isolation: A bird was considered affected if any embryos				
	died after each tracheal swab was used to inoculate 5 embryonated eggs. Each bird received a score from 0-5 based on the number of				
	embryos that died.				
	emoryos mai died.				
	Number of affected birds:				
	Group 1: 25/25 (unvaccinated control)				
	Group 3: 3/24				
	Group 13: 0/25 (non-challenged control)				
	-				
	Raw data on attached page.				
USDA Approval Date	June 3, 2008				

124 12M5.41 Page 12 of 19

Tracheal Ring Scores - Raw data

Tracheal Score, individual Results

Three 2 mm wide tracheal rings representing the upper third, middle third and lower third of the trachea of each bird were examined for ciliary activity. Tracheal ring sections were considered positive if less than 50% of the ring had discernible ciliary activity. Each bird received a score of 0, 1, 2, or 3 depending on how many sections were positive. A score of zero indicated that all sections were negative. A score of three indicated that all sections were positive. A score ≥ 1 is considered affected.

Group	vaccine	challenge	Unit	ID	Score
	None	Ark	11	431	3
İ				432	3
				433	3
				434	2
				435	3
				436	3
				437	2
				438	3
				439	3
				440	3
				441	2
				442	3
				443	3
			12	444	3
				445	3
				446	3
				447	2
				448	3
				449	3
				450	3
				451	3
				452	3
				453	3
				454	2
				455	3
3	Vaccine	Ark	5	356	0
				357	0
				358	0
				359	0
				360	0
				361	0
				362	0
				363	0
				365	0
				366	0
				367	0

124 12M5.41 Page 13 of 19

Group	vaccine	challenge	Unit	ID	Score
				368	0
			6	369	0
•				370	0
				371	1
				372	0
				373	0
				374	0
				375	0
				376	0
				377	0
				378	0
				379	0
				380	0
13	None	N/A	1	306	0
				307	0
				308	0
				309	0
				310	0
				311	0
				312	0
				313	0
				314	0
				315	0
				316	0
				317	0
				318	0
			2	319	0
				320	0
				321	0
				322	0
				323	0
				324	0
				325	0
				326	0
				327	0
				328	0
				329	0
				330	0

Ark = Infectious bronchitis virus, Arkansas type

N/A = Not applicable

124 12M5.41 Page 14 of 19

Virus Isolation (VI) - Raw data

VI Score, individual results

Each tracheal swab was used to inoculate 5 embryonated eggs. Each bird received a score of 0, 1, 2, 3, 4 or 5 depending on how many embryos died. A score of zero indicated that none of the embryos died and a score of 5 indicated that all five of the embryos died. A score ≥ 1 is considered affected.

Group	vaccine	challenge	Unit	ID	Score
1	None	Ark	11	431	5
				432	5
				433	5
				434	5
i				435	5
				436	5
				437	5
				438	4
				439	5
				440	4
				441	5
				442	5
				443	5
i			12	444	5
j l				445	5
i				446	5
				447	5
				448	5
				449	5
j l				450	5
				451	5
j				452	4
				453	5
j l				454	5
				455	4
3	Vaccine	Ark	5	356	0
j l				357	0
j l				358	0
				359	0
				360	0
j l				361	0
i				362	0
				363	0
j				365	0
[366	0
j				367	0
[368	0
			6	369	0
				370	0

124 12M5.41 Page 15 of 19

Group	vaccine	challenge	Unit	ID	Score
[371	0
				372	1
Į.				373	1
				374	1
				375	0
[376	0
[377	0
				378	0
Į.				379	0
				380	0
13	None	N/A	1	306	0
Į.				307	0
Į.				308	0
[309	0
Į.				310	0
[311	0
				312	0
				313	0
Į.				314	0
Į.				315	0
				316	0
Į.				317	0
				318	0
			2	319	
				320	
				321	0
				322	0
				323	0
[324	0
				325	0
				326	0
				327	0
				328	0
				329	0
				330	0

Ark = Infectious bronchitis virus, Arkansas type

N/A = Not applicable

124 12M5.41 Page 16 of 19

Study Type	Efficacy
Pertaining to	Newcastle disease
Study Purpose	Demonstrate efficacy against Newcastle disease
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	January 21, 2005

124 12M5.41 Page 17 of 19

Study Type	Efficacy
Pertaining to	Avian reovirus
Study Purpose	Demonstrate efficacy in stimulating passive immunity in offspring
	of birds vaccinated against reovirus
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	January 21, 2005

124 12M5.41 Page 18 of 19

Study Type	Safety
Pertaining to	ALL
Study Purpose	Demonstrate safety under field conditions
Product Administration	Intramuscularly (IM)
Study Animals	Chickens
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	February 14, 2005

124 12M5.41 Page 19 of 19